Imugene (ASX:$IMU) European Patent Announcement

Imugene Limited (ASX:IMU) has received a notification of intention to grant a patent for its PD1-Vaxx cancer vaccine from the European Patent Office. The patent application, covering manufacturing and method of treatment, is expected to proceed to grant in late 2023, with a maximum term expiring on 28 March 2038. The vaccine is currently in clinical development for non-small cell lung cancer (NSCLC) and colorectal cancer in 2024.

Imugene's CEO and MD, Ms Leslie Chong, on European Patent Grant

Receiving the notice that this European patent application will proceed to grant is an excellent milestone for the technology, and we are excited to continue developing the therapy to demonstrate the value of our PD1-Vaxx vaccine and to have a positive impact on the lives of many cancer patients.

Imugene's PD1-Vaxx Cancer Vaccine and Future Outlook

Imugene Limited (ASX:IMU) has secured a notification of intention to grant a European patent for its PD1-Vaxx cancer vaccine, marking a significant milestone for the company. The patent, once granted, will have a maximum term expiring on 28 March 2038. Imugene's CEO and MD, Ms Leslie Chong, expressed excitement about the development, emphasizing the potential positive impact on the lives of cancer patients. The PD1-Vaxx vaccine is designed to treat lung and colorectal cancer by interfering with PD-1/PD-L1 binding and interaction, aiming to produce an anti-cancer effect. Imugene's vision is to transform and improve cancer treatment, backed by a growing body of clinical evidence and peer-reviewed research. The company aims to be at the forefront of the rapidly growing global market for immuno-oncology therapies.